What the FDA labels say about taking them together
Avelumab and axitinib
Avelumab's FDA label of August 25, 2026 names axitinib in its warnings and precautions section, and axitinib's label names avelumab too. The avelumab label: “Discontinue BAVENCIO in combination with axitinib for Grade 3-4 events. Embryo-fetal toxicity:”
Check it at the source: the avelumab FDA label on DailyMed (effective August 25, 2026, EMD Serono, Inc.); the axitinib FDA label on DailyMed (effective March 12, 2026, U.S. Pharmaceuticals).
What does the avelumab label say about axitinib?
Avelumab label, warnings and precautionsDiscontinue BAVENCIO in combination with axitinib for Grade 3-4 events. ( 5.4 ) Embryo-fetal toxicity:
Source: FDA drug label (BAVENCIO), EMD Serono, Inc., effective August 25, 2026 (SPL set 5cd725a1-2fa4-408a-a651-57a7b84b2118), via openFDA; the full label on DailyMed
What does the axitinib label say about avelumab?
Axitinib label, warnings and precautionsWhen used in combination with avelumab or pembrolizumab, higher frequencies of Grade 3 and 4 ALT and AST elevation may occur.
Source: FDA drug label (INLYTA), NDA202324 (Pf Prism Cv), as published by U.S. Pharmaceuticals, effective March 12, 2026 (SPL set 8a903e31-936e-4ed7-8a59-59f32374f338), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Avelumab | Axitinib | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once